Clinical trials are research studies that are designed to determine if a medicine is safe and effective for patients. Patients may participate in ongoing clinical trials of Xencor’s investigational drug candidates if they meet certain enrollment criteria.
Condition: Acute Myelogenous Leukemia (AML); B-cell Acute Lymphoblastic Leukemia (B-ALL); Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN); Chronic Myeloid Leukemia (CML in blast phase)
Phase: Phase 1
The purpose of this study is to determine the safety and tolerability of weekly intravenous (IV) administration of XmAb14045 and to determine the maximally tolerated dose (MTD) after the first dose, and then to determine the MTD after second and subsequent infusions.
Conditions: B-cell Non-Hodgkin’s Lymphoma; Chronic Lymphocytic Leukemia (CLL); Small Lymphocytic Lymphoma (SLL)
Phase: Phase 1
The purpose of this study is to determine the safety and tolerability of weekly intravenous (IV) administration of XmAb13676 and to determine the maximally tolerated dose (MTD) after the first dose, and then to determine the MTD after second and subsequent infusions.
Conditions: Neuroendocrine Tumor (NET); Gastrointestinal Neoplasm (GIST)
Phase: Phase 1
This is a Phase 1, multiple dose, ascending dose escalation study; to define a MTD/RD and regimen consisting of a first “priming” dose and escalated subsequent doses of XmAb18087; to describe safety and tolerability; to assess PK and immunogenicity; and to preliminarily assess anti-tumor activity of XmAb18087 in subjects with advanced NET or GIST.
Conditions: Melanoma; Breast Carcinoma; Hepatocellular Carcinoma (HCC); Urothelial Carcinoma; Squamous Cell Carcinoma of the Head and Neck (SCCHN); Renal Cell Carcinoma (RCC); Colorectal Carcinoma (CRC); Non-small Cell Lung Carcinoma (NSCLC); Gastric or Gastroesophageal Junction Adenocarcinoma; Endometrial Carcinoma
Phase: Phase 1
This is a Phase 1, multiple dose, ascending dose escalation study to define a MTD/RD and regimen of XmAb20717, to describe safety and tolerability, to assess PK and immunogenicity, and to preliminarily assess anti-tumor activity of XmAb20717 in subjects with selected advanced solid tumors.
Conditions: Melanoma (Excluding Uveal Melanoma); Cervical Carcinoma; Pancreatic Carcinoma; Breast Carcinoma That is Estrogen Receptor, Progesterone Receptor, and Her2 Negative (TNBC); Hepatocellular Carcinoma; Urothelial Carcinoma; Squamous Cell Carcinoma of the Head and Neck; Nasopharyngeal Carcinoma; Renal Cell Carcinoma; Colorectal Carcinoma; Endometrial Carcinoma; Non-small Cell Lung Carcinoma; Small Cell Lung Cancer; Gastric or Gastroesophageal Junction Adenocarcinoma; Advanced Solid Tumors
Phase: Phase 1
This is a Phase 1, multiple dose, ascending dose escalation study to define a MTD/RD and regimen of XmAb23104, to describe safety and tolerability, to assess PK and immunogenicity, and to preliminarily assess anti-tumor activity of XmAb23104 in subjects with selected advanced solid tumors.
Information about Xencor’s clinical trials is available at www.clinicaltrials.gov.
Xencor, Inc. Headquarters
111 West Lemon Avenue
Monrovia, CA 91016
(626) 305-5900
Xencor, Inc. San Diego
12481 High Bluff Dr., Suite 200
San Diego, CA 92130
(858) 617-6155